

## 09. Global TB vaccine development: an update on epidemiological, clinical and preclinical investigations

**THE 46<sup>TH</sup> UNION  
WORLD CONFERENCE  
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA  
2-6 DECEMBER 2015

Friday, 04 December 2015, 17:30 - 18:45

Room MR 2.64-2.66

Type of session	Sponsored Satellite Symposium
Track	TB other
Track2 (optional)	TB epidemiology
Organised by	AERAS
Description	This symposium will provide updates regarding three critical aspects relevant to the development of TB vaccines: 1) an update of global TB epidemiology and cost burden, with attention to the spread and cost of drug-resistant TB strains (Robin Wood, UCT); 2) an update on the status of clinical trials of TB vaccines (Kristin Croucher, Aeras, SA); and 3) an update on the status of preclinical TB vaccine research and development efforts (Tom Scriba, SATVI). A panel discussion will follow the completion of the presentations (moderated by symposium co-chairs Nick Drager, TBVI and Lewis Schrager, Aeras)
Target audience	1. Persons interested in the rationale for accelerating development of TB vaccine efforts—particularly given the spread and cost of drug-resistant strains—and in learning of recent developments in clinical and preclinical TB vaccine development
Objectives	<ol style="list-style-type: none"> <li>1. Understand the extent and cost of drug-resistant Mtb strain spread, and importance of vaccine development to interdict this spread</li> <li>2. Understand the current status of clinical TB vaccine development</li> <li>3. Understand the key areas of preclinical TB vaccine research and development</li> </ol>
Keywords	Tuberculosis; vaccine; development
Coordinator(s)	Ellen Wilcox (USA)
Chair(s)	Lewis Schrager (USA), Nick Drager (Netherlands)
Presentations	<p><b>17:30 - 17:45</b> Global TB epidemiology and cost burden with attention to drug-resistant strains Robin Wood (South Africa)</p> <p><b>17:45 - 18:00</b> The clinical pipeline of Mtb vaccine candidates: current status Kristin Croucher (South Africa)</p> <p><b>18:00 - 18:15</b> Preclinical TB vaccine R&amp;D status: key focus areas Thomas Scriba (South Africa)</p> <p><b>18:15 - 18:45</b> Discussion</p>